OWCP (OWC Pharmaceutical Research) Debt-to-Equity: -0.01 (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research Debt-to-Equity?

OWC Pharmaceutical Research OWCP -90.00% Debt-to-Equity is -0.01 as of Sep. 2019.

OWC Pharmaceutical Research's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.03 Mil. OWC Pharmaceutical Research's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.02 Mil. OWC Pharmaceutical Research's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $-4.01 Mil. OWC Pharmaceutical Research's debt to equity for the quarter that ended in Sep. 2019 was -0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for OWC Pharmaceutical Research's Debt-to-Equity or its related term are showing as below:

OWCP's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

OWC Pharmaceutical Research  (OTCPK:OWCP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

OWC Pharmaceutical Research Debt-to-Equity Related Terms

OWC Pharmaceutical Research Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research Debt-to-Equity Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 2.48 0.00 0.00

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.01 -0.02 -0.01

OWCP vs PARNF, CANB, CXUS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OWC Pharmaceutical Research Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's Debt-to-Equity falls into.


OWC Pharmaceutical Research Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

OWC Pharmaceutical Research's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -9.44
=0.00

OWC Pharmaceutical Research's Debt to Equity Ratio for the quarter that ended in Sep. 2019 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.026 + 0.021) / -4.008
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.01 mean?
OWC Pharmaceutical Research (OWCP) has a Debt-to-Equity of -0.01 as of Sep. 2019. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's Debt-to-Equity too high?
OWC Pharmaceutical Research's current Debt-to-Equity is -0.01.
How does OWC Pharmaceutical Research's Debt-to-Equity compare to PARNF and CANB?
OWC Pharmaceutical Research's Debt-to-Equity of -0.01 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OWC Pharmaceutical Research and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OWC Pharmaceutical Research's current Debt-to-Equity is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current Debt-to-Equity of -0.01. The current Debt-to-Equity is -0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current Debt-to-Equity is -0.01 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.